Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T07:02:46.888Z Has data issue: false hasContentIssue false
  • English
  • Français

Chronicity, genes en behavior

Published online by Cambridge University Press:  18 September 2015

W.M.A. Verhoeven
Get access Rights & Permissions [Opens in a new window]

Summary

Since 1863 psychiatry is dominated by the nosological conceptual paradigm that was further stimulated by the introduction of the DSM-III. This has resulted in an ignorance of the European psychiatric diagnostic tradition and a loss of the necessary critical observations and descriptions of psychopathology. This unfortunate process may be observed in the diagnosis of psychiatric disorders in mentally retarded patients where entities such as atypical psychoses, unstable mood disorder and motivational deficit syndrome are not recognized in general. The enormous increase of neuroscienti-fic knowledge, particularly the impact of genetic and intracellular mechanisms in the pathophysiology of psychiatric disorders, warrants the use of a more dimensional and functional psychiatric paradigm. It concerns the effect of gene transcription on the expression of neurotransmitters and receptors that may account for an increased vulnerability or a relapsing course. A so called anticipatory treatment approach is therefore advocated.

Keywords

functional psychosesgeneticsgene transcriptionvulnerability
Type
Articles
Information
Acta Neuropsychiatrica , Volume 12 , Issue 4 , December 2000 , pp. 193 - 197
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Van Praag, HM. Nosologomanic. een aandocning van de psychiatric. Tijdschr Psychiatric 1999:41:703–712.Google Scholar
2.Ey, H. Etudes psychiatriques. Structures des psychoses aigues et déstructuration de la conscience. Paris. Desclée de Brouwer, 1954.Google Scholar
3.Leonhard, K. Aufteiling der endogenen Psychosen und ihre differenzierte Ätiologie. Stuttgart, George Thicme Verlag. 1955.Google Scholar
4.Rümke, HC. Een bloeiende psychiatrie in gevaar. Derde bundel studies en voordrachten over psychiatrie. Amsterdam. Scheltcma & Holkema NV. 1958. pp 11–30.Google Scholar
5.Verhoevcn, WMA. Curfs, LMG. Tuinier, S. Prader-Willi syndrome and cycloid psychoses. J Intellect Disabil Res 1998:42:455–462.Google Scholar
6.Verhoeven, WMA, Tuinier, S. Curfs, LMG. Prader-Willi psychiatric syndrome and velo-cardio-facial psychiatric syndrome. Genet Couns 2000:11:205–213.Google ScholarPubMed
7.Papolos, DF. Faedda, GL. Veit, S. Goldberg, R, Morrow, B. Kuchclapati, R. Shprintzen, RJ. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 1996:153:1541–1546.Google ScholarPubMed
8.Murphy, KC, Jones, LA. Owen, MJ. High rates of schizophrenia in adults with velo-cardio-facial svndromc. Arch Gen Psychiatry 1999:56:940–945.CrossRefGoogle Scholar
9.Amir, RE. Van den Veyver, IB. Wan, M. Tran, CO. Franke, U. Zoghbi, HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999:23:185–188.CrossRefGoogle ScholarPubMed
10.Plomin, R, DeFries, JC. McClearn, GE. Ruttcr, M. Behavioral Genetics. New York, W.H. Freeman and Company. 1997.Google Scholar
11.Nemeroff, CB. Psychopharmacology of affective disorders in the 21 st century. Biol Psychiatry 1998:44:517–525.Google Scholar
12.Hoovers, JMN. Meilink, CHM. Leschot, NJ. Fluorescentie-in-situhy-bridisatic bij het onderzoek naar chromosomale afwijkingen. Ned Tijdschr Geneeskd 1999:143:2265–2286.Google Scholar
13.Post, RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992:149:999–1010.Google ScholarPubMed
14.Licberman, JA. Sheitman, BB. Kinon, BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Ncuro Psychopharmacology 1997:17:205–229.Google Scholar
15.Haller, J, Abraham, I, Zelena, D, Juhasz, G, Makara, GB, Kruk, MR. Aggressive experience affects the sensitivity of neurons towards pharmacological treatment in the hypothalamic attack area. Behav Pharmacol 1998:9:469–475.CrossRefGoogle ScholarPubMed
16.De Kloet, ER. Brain corticosteroid receptor balance and homcostatic control. Front Neuroendocrinol 1991;12:95–164.Google Scholar
17.De Kloet, ER. Rots, NY. Cools, AR. Brain-corticosteroid hormone dialogue: slow and persistent. Cell Mol Neurobiol 1996:16:345–356.CrossRefGoogle ScholarPubMed
18.Verhoeven, WMA, Tuinier, S. Psychiatrie als neurowetenschap. Tijdschr Psychiatr 2000:257–263Google Scholar
19.Van Praag, HM. Leijnse, B. Neubewertung des Syndroms. Skizze einer funktionellen Pathologie. Psychiatr Neurol Neurochir 1965:8:50–66.Google Scholar
20.Van Praag, HM. Asnis, GM. Kahn, RS, Brown, SI. Korn, M. Harkavy Friedman, JM. Wetzler, S. Nosological tunnel vision in biological psychiatry. A plea for a functional Psychopathology. Ann NY Acad Sci 1990:600:501–510.CrossRefGoogle ScholarPubMed
21.Verhoeven, WMA, Tuinier, S. Neuropsychiatrische diagnostiek. In: Verhoeven, WMA, Tuinier, S. Curfs, LMG (eds). Diagnostiek en be-handeling van gedragsproblemen bij verstandelijk gehandicapten. Houtcn/Diegem. Cure and Care Development, Bohn Stafleu van Loghum. 1999. pp 35–46.Google Scholar
22.Dubovsky, SL. Thomas, M. Beyond specificity: effects of serotonin and serotonergic treatments on Psychobiological dysfunction. J Psychosom Res 1995:39:429–444.CrossRefGoogle ScholarPubMed
23.Bonhomme, N. Esposito, E. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: A review. J Clin Psychopharmacol 1998:18:447–454.CrossRefGoogle ScholarPubMed
24.Gabreëls, BATESwaab, DRDe Kleijn, PV. Seidah, G. Van de Loo, J|W. Van de Ven, WJM. Mertens, GJM, Van Lceuwen, FW. Attenuation of the polypeptide 7B2, prohormone convertase PC2.and vasopressin in the hypothalamus of some Prader-Willi patients: indications for a processing defect. J Clin Endocrinol Metabol 1998:83:591–599.CrossRefGoogle ScholarPubMed
25.De Wied, D. Peptides and behavior. Life Sci 1977:20:195–204.CrossRefGoogle ScholarPubMed
26.Den Boer, JA. Westenberg, HG. Oxytocin in obsessive compulsive disorder. Peptides 1992:13: 1083–1085.CrossRefGoogle ScholarPubMed
27.Saint-Cyr, JA, Taylor, AE. Nicholson, K. Behavior and the basal ganglia. In: Weiner, WJ, Lang, AE (eds). Behavioral Neurology of Movement Disorders. Advances in Neurology. New York. Raven Press. 1995. pp 1–28.Google Scholar
28.Tuinier, S. Verhoeven, WMA. Farmacotherapeutische strategieën. In: Verhoeven, WMA, Tuinier, S. Curfs, LMG (eds). Diagnostiek en Be-handeling van Gedragsproblemen bij Verstandelijk Gehandicapten. Houten/Diegem. Cure and Care Development. Bohn. Stafleu van Loghum. 1999. pp 88–99.Google Scholar
29.Marin, RS. Fogel, BS, Hawkins, J, Duffy, J. Krupp, B. Apathy: A treatable syndrome. J Neuropsychiatr Clin Neurosci 1995:7:23–30.Google Scholar
30.Verhoeven, WMA. Chroniciteit, genen en gedrag. Oratie, Erasmus Univcrsitcit Rotterdam 2000.Google Scholar